FEB 10, 2022
Academy Issues First Biosimilars Policy for Ophthalmic Practices
A new Academy policy statement recommends biosimilars should have sufficient research demonstrating their safety and effectiveness for treatment of eye diseases before they are routinely recommended for ophthalmologic use.